

Mundipharma in Diabetes

Introduction

Diabetes, especially type 2 diabetes, obesity and heart disease are increasing medical problems in the 21st century. Poor diets and modern lifestyles in a growing number of regions across the world are contributing to these problems, which are becoming critical worldwide health issues. In the EMEA region the patient demographic is ageing and this is expected to lead to increased numbers of diabetes and heart disease.

The Mundipharma network of independent associated companies in Europe recognises the threat to global health posed by diabetes and has partnered with Janssen to provide innovative diabetes therapies across Europe.

Mundipharma in diabetes – Unmet need and the company's commitment

Type 2 diabetes accounts for 90% of diabetes patients¹ and is a long-term disorder that is characterised by high blood sugar, insulin resistance, and a relative lack of insulin. Despite the availability of many treatments for type 2 diabetes, approximately half of patients have not reached treatment goals at any given time and more treatment options are needed which provide strong, sustained efficacy in lowering excess blood glucose.^{2,3}

The Mundipharma network of independent associated companies in Europe is proud to provide innovative medicines targeted at treating patients with type 2 diabetes. In September 2017, Mundipharma received exclusive rights to promote, distribute, and sell two innovative treatment options through our network of independent associated companies through an agreement with Janssen Pharmaceutical Companies of Johnson & Johnson.

INVOKANA[®] (canagliflozin) is an oral, once-daily sodium glucose co-transport 2 (SGLT2) inhibitor which works by excreting excess glucose via the urine.⁴ The development of canagliflozin included a comprehensive global Phase 3 clinical trial programme, which was submitted as part of the licencing process. This is one of the largest late stage development programmes for a medicinal product for the treatment of type 2 diabetes conducted to date.

Many patients with type 2 diabetes often fail to maintain glucose control over the long term and go on to take a combination of several glucose lower agents. VOKANAMET[®] is a fixed-dose therapy combining canagliflozin and immediate release metformin hydrochloride (a commonly used glucose lowering agent) in a single tablet.⁵

Mundipharma is proud to provide both INVOKANA[®] and VOKANAMET[®] in countries in the European Economic Area (EEA) and Switzerland where the products have obtained Pricing and Reimbursement Approvals.

Mundipharma has a strong heritage across Europe in specialist driven primary care and, through our work in diabetes, we further strengthen our commitment to making available innovative medicines that add real value to patients and healthcare systems.

For more information, please visit:

<https://www.mundipharma.com/about-mundipharma/global-network/>

References

- 1 IDF. Diabetes Atlas, 8th edition. Available at: <https://www.idf.org/e-library/epidemiology-research/diabetes-atlas.html> Last accessed July 2018.
- 2 Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. *Trends Pharmacol Sci.* 2011;32(2):63-71.
- 3 Nau DP. Recommendations for Improving Adherence to Type 2 Diabetes Mellitus Therapy – Focus on Optimising Oral and Non-Insulin Therapies. *Am J Manag. Care.* 2012;18:549-554.
- 4 INVOKANA SmPC. Available at: <https://www.medicines.org.uk/emc/product/8855> Last accessed July 2018.
- 5 VOKANAMET SmPC. Available at: <https://www.medicines.org.uk/emc/product/8261> Last accessed July 2018.